353 results
Page 12 of 18
8-K
EX-99.1
kuf9o hfen8oq3hw7u
31 Oct 12
Acorda Therapeutics Reports Third Quarter 2012 Financial Results
12:00am
8-K
EX-99.1
391 tfmrr7h378
16 Oct 12
Acorda Therapeutics Announces Hatch-Waxman Extension of AMPYRA® (dalfampridine) Sustained-Release Formulation Patent
12:00am
8-K
EX-99.1
1hi 72x6hk3vt
10 Oct 12
Other Events
12:00am
8-K
lk4efm2 yjgtj0hyri
10 Oct 12
Other Events
12:00am
8-K
EX-99.1
ldhew531jx6w6607
9 Oct 12
Acorda Therapeutics Names Jane Wasman President, International
12:00am
8-K
EX-99.1
onzm6r
28 Aug 12
Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction
12:00am
8-K
EX-99.1
ju3qghj
13 Aug 12
Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine-ER
12:00am
8-K
EX-99.1
6u33w
31 Jul 12
Acorda Therapeutics Reports Second Quarter 2012 Financial Results
12:00am
8-K
EX-99.1
98956ks2 r3jwl1vfoe
12 Jun 12
Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits
12:00am
8-K
zp8x330ell2xg60ml6t
31 May 12
Other Events
12:00am
8-K
EX-99.1
j5kaev 9xduabt
31 May 12
Other Events
12:00am
8-K
EX-99.1
5gwmraa pi
3 May 12
Acorda Therapeutics Reports First Quarter 2012 Financial Results
12:00am
8-K
4lz8gfhbz rrhro
25 Apr 12
Acorda Therapeutics Presents AMPYRA® Long-Term Safety and Efficacy Data at 64th American Academy of Neurology Annual Meeting
12:00am
8-K
EX-99.1
kp2plizwkp451
25 Apr 12
Acorda Therapeutics Presents AMPYRA® Long-Term Safety and Efficacy Data at 64th American Academy of Neurology Annual Meeting
12:00am